Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.
Standard
Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. / Westerhout, K Y; Verheggen, B G; Schreder, C H; Augustin, Matthias.
In: J MED ECON, Vol. 15, No. 5, 5, 2012, p. 906-917.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.
AU - Westerhout, K Y
AU - Verheggen, B G
AU - Schreder, C H
AU - Augustin, Matthias
PY - 2012
Y1 - 2012
N2 - An economic evaluation was conducted to assess the outcomes and costs as well as cost-effectiveness of the following grass-pollen immunotherapies: OA (Oralair; Stallergenes S.A., Antony, France) vs GRZ (Grazax; ALK-Abelló, Hørsholm, Denmark), and ALD (Alk Depot SQ; ALK-Abelló) (immunotherapy agents alongside symptomatic medication) and symptomatic treatment alone for grass pollen allergic rhinoconjunctivitis.
AB - An economic evaluation was conducted to assess the outcomes and costs as well as cost-effectiveness of the following grass-pollen immunotherapies: OA (Oralair; Stallergenes S.A., Antony, France) vs GRZ (Grazax; ALK-Abelló, Hørsholm, Denmark), and ALD (Alk Depot SQ; ALK-Abelló) (immunotherapy agents alongside symptomatic medication) and symptomatic treatment alone for grass pollen allergic rhinoconjunctivitis.
KW - Adult
KW - Germany
KW - Humans
KW - Cost-Benefit Analysis
KW - Treatment Outcome
KW - Antigens, Plant/immunology
KW - Desensitization, Immunologic/economics
KW - Poaceae/adverse effects/immunology
KW - Pollen/adverse effects/immunology
KW - Quality-Adjusted Life Years
KW - Rhinitis, Allergic, Seasonal/drug therapy/immunology
KW - Adult
KW - Germany
KW - Humans
KW - Cost-Benefit Analysis
KW - Treatment Outcome
KW - Antigens, Plant/immunology
KW - Desensitization, Immunologic/economics
KW - Poaceae/adverse effects/immunology
KW - Pollen/adverse effects/immunology
KW - Quality-Adjusted Life Years
KW - Rhinitis, Allergic, Seasonal/drug therapy/immunology
M3 - SCORING: Journal article
VL - 15
SP - 906
EP - 917
JO - J MED ECON
JF - J MED ECON
SN - 1369-6998
IS - 5
M1 - 5
ER -